CLINICAL_TRIALS
trial_result
· 2024-11-20
Clinical Trial Update: Neoadjuvant PRRT With Y-90-DOTATOC in pNET [Phase 2]
Summary
Phase 2 neoadjuvant radiopharmaceutical therapy with Y-90-DOTATOC for pancreatic neuroendocrine tumors has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: European Institute of Oncology | Conditions: Pancreatic Neuroendocrine Tumor | Phase 2 | Status: TERMINATED